Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in elderly patients has been restricted by substantial myelosuppression and infection. We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Jan 2014

Volume: 15

Issue: 1

Affiliations

[1 ] Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: sobrien@mdanderson.org.

[2 ] Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY, USA.

[3 ] Division of Hematology and Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA.

[4 ] Willamette Valley Cancer Institute and Research Center/US Oncology Research, Springfield, OR, USA.

[5 ] Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[6 ] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

[7 ] Vermont Cancer Center, University of Vermont, VT, USA.

[8 ] Texas Oncology, US Oncology Research, Tyler, TX, USA.

[9 ] Department of Pathology, The Ohio State University, Columbus, OH, USA.

[10 ] Pharmacyclics, Sunnyvale, CA, USA.

Article

Publisher Item ID: S1470-2045(13)70513-8 Mid ID: NIHMS609490

DOI: 10.1016/S1470-2045(13)70513-8

PMC ID: 4134524

PubMed ID: 24332241

SO-VID: 3cf7320d-543b-420e-b2da-670e4b28c06e

History

Data availability:

Comments

Comment on this article

scite_

Cited by 139

See all cited by

- Version 1